J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN a ...
Zacks.com on MSN3h
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi DrugJ&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Boing Boing on MSN4h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback